Preemptive Second Kidney Transplant Outcomes by Induction Type in the United States.

[1]  T. Alexy,et al.  Kidney Allograft and Recipient Survival After Heart Transplantation by Induction Type in the United States , 2021, Transplantation.

[2]  A. Israni,et al.  OPTN/SRTR 2019 Annual Data Report: Kidney , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  D. Roelen,et al.  Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients , 2020, Frontiers in Immunology.

[4]  J. Pascual,et al.  Gender differences in cancer risk after kidney transplantation , 2019, Oncotarget.

[5]  C. Ferrand,et al.  Uraemia-induced immune senescence and clinical outcomes in chronic kidney disease patients. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  K. Jhaveri,et al.  Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network , 2017, Clinical kidney journal.

[7]  Wen-li Song,et al.  Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients , 2017, Medicine.

[8]  A. Mehta,et al.  Premature T Cell Senescence in Pediatric CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[9]  J. Aguado,et al.  Immune risk phenotype in kidney transplant recipients: a reliable surrogate for premature immune senescence and increased susceptibility to infection? , 2016, Transplant infectious disease : an official journal of the Transplantation Society.

[10]  G. Opelz,et al.  Efficacy and safety of antibody induction therapy in the current era of kidney transplantation. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  M. Fouad,et al.  Insurance Type and Solid Organ Transplantation Outcomes: A Historical Perspective on How Medicaid Expansion Might Impact Transplantation Outcomes. , 2016, Journal of the American College of Surgeons.

[12]  J. Gill,et al.  Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis , 2016, Transplantation.

[13]  J. Schold,et al.  Clinical Outcomes Associated With Induction Regimens Among Retransplant Kidney Recipients in the United States , 2015, Transplantation.

[14]  R. Mannon,et al.  The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? , 2015, Current Transplantation Reports.

[15]  P. Tiberghien,et al.  Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipients. , 2014, Journal of the American Society of Nephrology : JASN.

[16]  J. Gill,et al.  Risks and Benefits of Preemptive Second Kidney Transplantation , 2013, Transplantation.

[17]  H. Sollinger,et al.  Alemtuzumab as compared to alternative contemporary induction regimens , 2012, Transplant International.

[18]  D. Landsittel,et al.  Long-Term Effects of Alemtuzumab on Regulatory and Memory T-Cell Subsets in Kidney Transplantation , 2012, Transplantation.

[19]  S. Mulgaonkar,et al.  Alemtuzumab induction in renal transplantation. , 2011, The New England journal of medicine.

[20]  S. Vowler,et al.  Features of immune senescence in liver transplant recipients with established grafts , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[22]  W. Weimar,et al.  The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  M. Stegall,et al.  Identifying Specific Causes of Kidney Allograft Loss , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  L. Bubendorf,et al.  Risk factors for polyoma virus nephropathy , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  V. Sharma,et al.  Epidemiology of BK Virus in Renal Allograft Recipients: Independent Risk Factors for BK Virus Replication , 2008, Transplantation.

[26]  P. Vereerstraeten,et al.  HLA Mismatches Remain Risk Factors for Acute Kidney Allograft Rejection in Patients Receiving Quadruple Immunosuppression With Anti-Interleukin-2 Receptor Antibodies , 2008, Transplantation.

[27]  A. Kirk,et al.  Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  A. Kirk.  Induction Immunosuppression , 2006, Transplantation.

[29]  L. Agodoa,et al.  Posttransplant Lymphoproliferative Disorders after Renal Transplantation in the United States in Era of Modern Immunosuppression , 2005, Transplantation.

[30]  G. Opelz,et al.  Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  D. Dunn,et al.  2,500 Living Donor Kidney Transplants: A Single-Center Experience , 2001, Annals of surgery.